Vipergen is a biotechnology company based in Copenhagen, focused on transforming drug discovery through screening DNA encoded libraries (DELs) using innovative, proprietary technologies. By enabling screening directly in living cells under physiologically relevant conditions, Vipergen expands the accessible drug target space and accelerates high-quality lead generation.
A core element of Vipergen’s discovery platform, DELs in Cells, is its patented screening method, designed to identify binding events between therapeutic candidates and their target proteins. During screening, binding interactions generate ligated DNA fragments specific for the interactions, which are subsequently analyzed by next-generation sequencing.
Importantly, due to the immense size of the libraries (approximately 500 million compounds per library), binding events have to be distinguished from random events. To confidently identify the true binders, Vipergen must therefore sequence at very high depth, ensuring robust statistical differentiation between binding compounds and background.
To support this requirement, Vipergen selected the G400, which provides the high throughput, precision, and cost-efficient price per read needed to analyze large sequencing volumes without compromising data quality.
“Our discovery workflows rely on sequencing depth and quality to enable identification of hits. Access to reliable high-throughput sequencing at an efficient cost per read is essential,” said Dr. Leif Kongskov Larsen, Director Biology at Vipergen
The G400 enables Vipergen to:
Sequence large numbers of DNA fragments derived from screening experiments
Confidently distinguish hits from non-binders through depth-driven resolution
Scale discovery programs while maintaining economic efficiency
Support rapid discovery and fast method optimization
At MGI, we are proud to support Vipergen’s work of drug discovery, demonstrating how next-generation sequencing platforms are increasingly applied beyond traditional genomics into therapeutic innovation.
MGI and Vipergen continue to explore ways to highlight how sequencing scalability and affordability play a critical role in modern drug discovery.
Learn more about Vipergen and its services
Learn more about the G400
Share
